News Release PathoQuest Appoints Dr. Klaus Binder to Company’s Board of Directors PathoQuest, the leading expert in GMP next-generation sequencing (NGS) services for biosafety testing, has announced that Klaus Binder, PhD has been appointed as a non-executive director...
Press Release Oxford Nanopore and PathoQuest announce next step of strategic collaboration to bring to market the first sequencing-based quality control test for biopharma genetic characterisation Nanopore sequencing combined with PathoQuest expertise offers a new...
Press Release Oxford Nanopore and PathoQuest announce the first steps in a strategic collaboration to bring the first GMP-accredited, nanopore-based biologics genetic characterisation test to market Nanopore sequencing offers a transformational new approach for robust...
Press Release PathoQuest Announce the Opening of its New U.S. Facility The Leading Experts in NGS Biosafety Testing and Characterization of Biopharmaceuticals Launch New Capabilities in the Critical U.S. Market Wayne, PA, and Paris, France – October 4, 2022 –...
Press Release PathoQuest Appoints Rainer Metzger, Ph.D. as Chairman of the Board of Directors PARIS, FRANCE – September 1st, 2022 – PathoQuest, a pioneer of next-generation sequencing (NGS)-based testing solutions for the quality control of biologics, today...
Press Release PathoQuest Receives GMP Certification for its NGS-based Quality Control Testing Services Pour la version en français de ce communiqué de presse : cliquez ici PARIS, FRANCE – November 24, 2021 – PathoQuest, a leading contract research organization (CRO)...